No phaseCompleted
RESOLUTE ONYX China Single Arm Study
A Single Arm Clinical Evaluation of Safety and Efficacy of the Medtronic Resolute Onyx™ Zotarolimus-Eluting Coronary Stent System in the Treatment of Subjects Eligible for Percutaneous Transluminal Coronary Angioplasty (PTCA) in China
- Sponsor
- Medtronic Vascular (Industry)
- Enrollment
- 591 enrolled
- Conditions
- Ischemic Heart Disease; Stenotic Coronary Lesion; Cardiovascular Diseases; Arteriosclerosis; Coronary Artery Disease
- Interventions
- Resolute Onyx™ Zotarolimus-Eluting Coronary Stent System
- Ages
- adults, older adults
- Registry
- NCT03471845
Full record on ClinicalTrials.gov
From the registry
It is a single arm clinical evaluation of safety and efficacy of the Medtronic Resolute Onyx™ zotarolimus-eluting coronary stent system in subjects who are eligible for percutaneous transluminal coronary angioplasty (PTCA) in de novo lesions amenable to treatment with Resolute Onyx™ Stent System in China.
Primary outcomes
- Target Lesion Failure (TLF)
History
Last registry update
Study completion
Primary completion
Started
Registered